GSK Bets $1 Billion on China's SiranBio and Its Novel siRNA 'Fat-Reducing' Drug SA030, Poised for Combination with GLP-1 Therapies

May 07, 2026 20:03 CST Updated 20:03

SiranBio

Innovative siRNA Drug Developer

Huadong Medicine

Large Comprehensive Pharmaceutical Product Developer

May 6,SiranBioAnnouncement withGSKReach an exclusive global licensing agreement and sign a cooperation for SA030.

According to the terms of the agreement,GSKWill pay the upfront payment, as well as future milestone payments based on the successful achievement of development, registration, and commercialization milestones, with a total amount up to10.05Billion US dollars; At the same time, a tiered royalty will be paid based on global net product sales (excluding mainland China, Hong Kong, Macao, and Taiwan). SiranBio will take the lead in completingSA030TheIPhase clinical trial, followed byGSKResponsible for global development, registration, and commercialization within the cooperative region, both parties accelerate drug implementation through division of labor and collaboration.

GSKThe global resources accelerate the international expansion of products, while retaining the most important local market value for the company, demonstrating SiranBio'sBDClear strategic boundaries in cooperation.

SA030Is a potential first-in-class, long-acting small interfering RNA (siRNA) Oligonucleotides, currently in the development stage, are intended for the treatment of metabolic and cardiovascular diseases.

SA030 has recently advanced to Phase I clinical trials, targeting activin receptor-like kinase 7 (ALK7) play a role, and this pathway is a well-established therapeutic mechanism in the field of cardiometabolic diseases. Preclinical studies have shown that SA030 possesses differentiated long-acting properties, which can intervene in fundamental inflammation associated with cardiometabolic risks through adipocyte-targeted delivery and a low-frequency dosing regimen.

In addition, SA030 has the capability toGLP-1 AgonistThe complementary and unique mechanism of SGLT2 inhibitors supports potential future combination therapy regimens to reduce residual cardiometabolic risks that existing therapies have not fully addressed.

SiranBio's overseas expansion this time is by no means accidental, and behind it lies a solid technical platform andsiRNAMedicine2.0Precise positioning of the times.

ExceptSA030In addition, another core product of SiranBioSA1211Similarly, it is highly significant as an industry benchmark. As the world's first innovation capable of simultaneously targeting the hepatitis B virusHBxGenes and Hepatocyte SurfacePD-L1Dual-target genesiRNA，SA1211Is the world's first single-molecule dual-target to enter clinical trialssiRNADrug, in2025Year10Monthly AcquisitionNMPAClinical Trial Permit.

In addition, SiranBio has also collaborated with Huadong Medicine on innovative weight loss solutions.siRNATherapy Field Reaches Strategic Cooperation, Completes Preclinical Candidate Compound Confirmation, Officially Enters Preclinical Research Stage.

Currently, the company has established a comprehensive pipeline covering areas such as anti-chronic hepatitis B, cardiovascular and metabolic diseases, and obesity.4Clinical stage andINDPrevious Stage Drugs.

Dr. Zhiwei Yang, Founder and CEO of SiranBioRepresentation："We are deeply honored to gain recognition from a top multinational pharmaceutical company this time. The resource advantages and clinical development capabilities possessed by GlaxoSmithKline will greatly accelerate the transformation of SiranBio's innovative R&D pipeline into therapeutic drugs, benefiting more patients in the fields of fat reduction and chronic diseases related to fat."Multiple groups."

Dr. Kaivan Khavandi, Senior Vice President of GlaxoSmithKline, Head of Respiratory, Immunology & Inflammation (RI&I) R&D, and Head of Translational and Development SciencesRepresentation："SA030, based on our emerging R&D pipeline targeting inflammation, fibrosis, and vascular pathogenic drivers, is expected to help improve patient outcomes. GSK's deep technical expertise in small nucleotide drugs, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), will also benefit the development of SA030."

·END·

Previous Issues·Selected